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ROS/RNS scavengersExcess superoxide (O2
•−) and nitric oxide (NO•) forms peroxynitrite (ONOO−) during cardiac ischemia reperfu-
sion (IR) injury, which in turn induces protein tyrosine nitration (tyr-N). Mitochondria are both a source of and
target for ONOO−. Our aim was to identify speciﬁc mitochondrial proteins that display enhanced tyr-N after
cardiac IR injury, and to explore whether inhibiting O2•−/ONOO− during IR decreases mitochondrial protein
tyr-N and consequently improves cardiac function. We show here that IR increased tyr-N of 35 and 15 kDa
mitochondrial proteins using Western blot analysis with 3-nitrotyrosine antibody. Immunoprecipitation (IP)
followed by LC–MS/MS identiﬁed 13 protein candidates for tyr-N. IP andWestern blot identiﬁed and conﬁrmed
that the 35 kDa tyr-N protein is the voltage-dependent anion channel (VDAC). Tyr-N of native cardiac VDACwith
IRwas veriﬁed on recombinant (r) VDACwith exogenousONOO−.We also found that ONOO− directly enhanced
rVDAC channel activity, and rVDAC tyr-N induced by ONOO− formed oligomers. Resveratrol (RES), a scavenger
of O2
•−/ONOO−, reduced the tyr-N levels of both native and recombinant VDAC, while L-NAME, which inhibits
NO• generation, only reduced tyr-N levels of native VDAC. O2•− and ONOO− levels were reduced in perfused
hearts during IR by RES and L-NAME and this was accompanied by improved cardiac function. These results
identify tyr-N of VDAC and show that reducing ONOO− during cardiac IR injury can attenuate tyr-N of VDAC
and improve cardiac function.
© 2012 Published by Elsevier B.V.1. Introduction
Mitochondrial dysfunction during cardiac ischemia (I) and reperfu-
sion (R) injury is associated with Ca2+ overload, excess emission of re-
active oxygen species (ROS) [1–3] and reactive nitrogen species (RNS)
[4,5] that can lead to deleterious post-translational modiﬁcations
(dPTMs) of mitochondrial proteins [6]. Superoxide (O2•−), the origin ofOO−, peroxynitrite; tyr, tyro-
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sevier B.V.most O2 -derived free radicals, is overproduced and under scavenged
during cardiac IR injury [1,7]. Under hypoxic or ischemic conditions,
the mitochondrial electron transport chain (ETC) is initially in a highly
reduced state [1], which results in electron leak so that O2 is reduced
to O2•−. During reperfusion, O2•− production, initiated during ischemia,
is further exacerbated [1] because of diminished ADP levels, abundant
O2, and poor ROS scavenging capability. Nitric oxide (NO•), a precursor
of RNS, may also increase during IR [8,9]. When O2•− is in excess it
reacts with available NO• to generate peroxynitrite (ONOO−) [2,10], a
highly reactive non-radical and a strong marker of RNS-induced cell
cytotoxicity. Indeed, amarked increase in ONOO− occurs during cardiac
IR injury [4,5] and a reduction in injury is associated with decreased
release of ONOO− [4,5]. O2•− is a charged and diffusion limitedmolecule
generated inmitochondria, whereas NO• is an uncharged, and diffusible
molecule that easily traverses mitochondrial membranes. ONOO− has
a half-life of about 3–5 ms in mitochondria and is a strong oxidant of
mitochondrial proteins and lipids lying in close proximity [3]. Thus
mitochondria can be both a site for ONOO− production and a target of
ONOO−-induced dPTMs [3]. For example, ONOO−mediates inactivation
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nitration and oxidation of critical tyrosine residues [11,12]. However,
the most vulnerable protein sites, the mechanisms by which ONOO−
mediates damage to mitochondria, and the cardiac functional conse-
quences are not well known.
In general, ONOO− can directly oxidize molecules, decompose to
NO2• and •OH, or react with CO2 to form CO3•− and NO2• [13]. These
free radicals induce protein nitration, especially of exposed tyrosine
(tyr) residues to form 3-nitrotyrosine (3-NT) [6]. Tyrosine nitration
(tyr-N) is an established marker not only for RNS-induced stress
resulting from ONOO− and its radical products, but also for ONOO−
mediated cytotoxicity; once formed, 3-NT is relatively stable and
the nitration can result in deleterious protein structural and function-
al changes [3,13]. Tyr-N may itself cause protein dysfunction and it
may also prevent tyr phosphorylation by tyr kinases [14]. Although
tyr-N is widely used as a biological assay indicative of ONOO− gener-
ation, it is acknowledged that ONOO− can also nitrate tryptophan and
phenylalanine and that it also oxidizes other sites, e.g. FeS centers,
protein thiols, and lipids [10]. Moreover, tyr-N may be induced by
ONOO− independent oxidants like the gas NO2• formed by oxidation
of NO2−(itself an oxidized product of NO•) in the presence of H2O2 by
peroxidase, but high concentrations of this labile NO2• product are
likely required to induce tyr-N [15].
Both in vivo and in vitro evidence indicates that proteins involved in
oxidative phosphorylation and apoptosis can be nitrated in various
diseases and disorders [16]. Nitration of proteins has been observed
after IR injury [17–22], but the effect of IR on inducing irreversible
dPTMs that alter the structure and function of key mitochondrial pro-
teins has not been well examined. Liu et al. [17] indirectly identiﬁed
10 mitochondrial proteins including 4 subunits from the oxidative
phosphorylation system, ﬁve enzymes in the matrix, and the voltage-
dependent anion channel (VDAC) that were nitrated after IR injury
using two-dimensional gel electrophoresis (2-DE) gel and mass spec-
trometry (MS) analysis. However, the identiﬁcation of these tyr-N
proteins using speciﬁc antibodies, and the determination of the speciﬁc
sites of tyr-N by MS have not been undertaken; nor is it known if nitra-
tion of mitochondrial proteins during cardiac IR could be reduced by
ROS/RNS scavenging or by inhibiting nitric oxide synthase (NOS), and
if identiﬁed nitrated mitochondrial proteins exhibit altered function.
We proposed that some key mitochondrial proteins undergo tyr-N
during IR injury and that attenuating formation of ONOO− reduces
tyr-N of these proteins and leads to improve cardiac function. Thus
our ﬁrst objective was to identify speciﬁc mitochondrial proteins that
undergo enhanced tyr-N after cardiac IR injury. We identiﬁed VDAC as
a tyr-N protein, and so pursued VDAC as a focus for additional studies.
Although other proteins can be nitrated during IR injury, we focused
on VDAC based on our initial results. We probed ONOO− induced tyr-N
of recombinant (r) VDAC and its effect on changing rVDAC channel ac-
tivity. In addition we tested if resveratrol (RES, trans-3, 4′, 5-
trihydroxystilbene), a putative O2•− and ONOO− scavenger, and
NG -nitro-L-argininemethyl ester (L-NAME), an unspeciﬁc NOS inhibitor,
could reduce the extent of tyr-N in mitochondrial proteins in association
with reduced levels of O2•− and ONOO− and improve functional recovery
after IR injury in intact hearts. Our focus on the molecular aspect in this
studyprovides amoremechanistic insight intohowROS/RNS impactsmi-
tochondrial proteins and leads to the functional changes in myocardial
function during IR. Such an in depth approach could provide for better
strategies to mitigate IR injury.
2. Methods
2.1. Isolated heart preparation and protocols
Hearts in situ cannot be used to detect O2•− and ONOO−, so isolated
hearts from guinea pigs were utilized to directly correlate changes in
total cardiac oxidative stress and function in isolated mitochondriaafter IR injury. Our animal protocols conformed to the Guide for
the Care and Use of Laboratory Animals (National Institutes of Health
No. 85‐23, Revised 1996) and were described previously [4,7,23,24]
(see detailed descriptions in the Online Supplement Materials and
Methods). After 30 min of global ischemia, or after 10, 30, or 60 min re-
perfusion, hearts were removed and mitochondria were immediately
isolated. In the treated groups either 100 μmol/L L-NAME or 10 μmol/L
RES was perfused for 10 min up to initiation of global ischemia so that
the drug remained in the hearts during ischemia. RES, 10 μmol/L, is car-
dioprotective in isolated rat hearts [25] and 100 μmol/L L-NAME blocks
increased ONOO− production in 17 °C-perfused isolated hearts [24].
2.2. Detection of O2
•− and ONOO− in isolated hearts
The intracellular ﬂuorescent probe dihydroethidium (DHE)
(Molecular Probes) was used to assess O2•− emission in isolated hearts
as described previously (see Online SupplementMaterials andMethods)
[7,23,24,26]. After attaining stability, hearts were loaded with 10 μmol/L
DHE for 20 min followed bywashout of residual DHE for another 20 min.
Dityrosine (DiTyr) was used to detect ONOO− formation indirectly
as described previously (see Online SupplementMaterials andMethods)
[24]. ONOO− reacts with continuously perfused L-tyrosine (0.3 mmol/L)
to form the ﬂuorescent dimer DiTyr [9], a stable product at tissue pH
[27]. DHE loaded/L-tyrosine perfused hearts were treated with/without
RES/L-NAME before ischemia, followed by IR.
2.3. Isolation of mitochondria
Cardiac mitochondria were isolated at the end of each functional
study using well-established methods in our laboratory [28–30]
with minor modiﬁcations. All isolation procedures were carried out
at 4 °C. Hearts were minced into very small pieces in a chilled isola-
tion buffer containing 200 mmol/L mannitol, 50 mmol/L sucrose,
5 mmol/L KH2PO4, 5 mmol/L MOPS, 0.1% fatty acid free bovine
serum albumin (BSA) and 1 mmol/L EGTA, at pH 7.15, then homoge-
nized in 2.65 ml isolation buffer containing protease (5 U/ml, Sigma
Cat: P-5495) for 15 s with an ultrasonic homogenizer. After this,
15 ml of isolation buffer containing protease inhibitors (Roche, Com-
plete protease inhibitor cocktail tablets) was added rapidly to the ho-
mogenate followed by another 15 s of homogenization. The slurried
homogenates were centrifuged at 10,000 g for 5 min, and then the
pellet was resuspended in isolation buffer containing protease inhib-
itors and centrifuged at 8000 g for another 10 min. After that, the pel-
let was resuspended in isolation buffer containing protease inhibitors
and spun at 750 g for 10 min; then the supernatant was collected and
centrifuged again at 8000 g. The resulting mitochondrial pellet was
resuspended in isolation buffer containing protease inhibitors and
stored at −80 °C for later use. The amount of mitochondrial protein
was assessed using Bio-Rad protein assay with BSA as the standard.
2.4. Immunoprecipitation of mitochondrial proteins
Immunoprecipitation (IP)was performed as described before [17,31]
with minor changes. Mitochondria were pelleted and then lysed in RIPA
buffer containing 50 mmol/L Tris-Cl pH 7.4, 150 mmol/L NaCl, 1% sodium
deoxycholate, 1% Triton X-100, 0.1% SDS and protease inhibitors on
ice for 30 min. The sample was pre-cleared with 30 μl protein G
Sepharose-4B beads (Invitrogen) for 1 h at 4 °C with constant end-
over-end shaking and then centrifuged at 3000 g for 5 min. The superna-
tant was collected, adjusted to 2 mg/ml protein concentration with RIPA
buffer containing protease inhibitors, and subjected to IP with an anti-3-
nitrotyrosine monoclonal antibody (anti-3-NT, Millipore) or anti-VDAC
antibody (Sigma) at 4 °Cwith constant end-over-end shaking overnight.
The next day, after adding 30 μl protein G Sepharose-4B beads, the mix-
ture was incubated for another 2 h under the same conditions as above.
The beads were collected and exhaustively washed (ﬁve times) with
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taining 50 mmol/L Tris-Cl, 10% glycerol, 500 mmol/Lβ-mercaptoethanol,
2% SDS, 0.01% w/v bromophenol blue and protease inhibitors at pH 7.4
and boiled at 95 °C for 5 min. The immunoprecipitated proteins were
separated using SDS-PAGE. The gels were silver stained or subjected to
Western blot analysis.
2.5. Two-dimensional gel electrophoresis (2-DE)
2-DE was performed with the IEF/Criterion gel system (Bio-Rad).
Mitochondrial pellets were lysed in lysis buffer containing 7.8 mol/L
urea, 2.2 mol/L thiourea, 4% CHAPS, and protease inhibitors on ice
for 30 min, then desalted twice with Amicon 3 kDa (Millipore).
After adding 65 mmol/L DTT and 1% Bio-Lyte ampholyte (pH3-10),
about 800 μg of protein from each sample was immediately loaded
onto an 11-cm nonlinear pH 3–10 IPG strip (Bio-Rad). The strips
were rehydrated at 50 V for 12 h and then focused under the follow-
ing conditions: voltage was ﬁrst increased to 250 V over 20 min
followed by a linear increase to 8000 V over 70 min and then held
at 8000 V until 26 kVh was attained. The focused IPG strips were
then equilibrated for 15 min in 0.375 mol/L Tris-Cl, pH 8.8, 6 mol/L
urea, 20% glycerol, 2% SDS and 2% DTT followed by 15 min in
0.375 mol/L Tris-Cl, pH 8.8, 6 mol/L urea, 20% glycerol, 2% SDS and
2.5% iodoacetamide. The equilibrated strips were loaded on pre-cast
gels (Criterion™ 10%, 11 cm; Bio-Rad) for the seconddimension separa-
tion. The gels were run at 150 V for 70 min and then transferred onto
polyvinylidene diﬂuoride (PVDF) membranes for Western blot analysis
with anti-VDAC and anti-3-NT antibodies.
2.6. Western blot analysis
Mitochondrial pellets were lysed in sample buffer and boiled at
95 °C for 5 min.Mitochondrial samples (100 μg) or immunoprecipitates
were resolved by SDS-PAGE and transferred onto PVDF membranes.
Membranes were incubated with speciﬁc primary antibodies against
3-NT, VDAC (Cell Signaling), and ANT (adenine nucleotide translocator,
Santa Cruz). Washed membranes were incubated with the appropriate
secondary antibody conjugated to horseradish peroxidase, then im-
mersed in an enhanced chemiluminescence detection solution (GE
Healthcare) and exposed to X-Ray ﬁlm for autoradiography. For moni-
toring loaded protein amounts, VDAC or ANT protein was used as load-
ing controls because VDAC and/or ANT are mitochondrial membrane
proteins and their detection conﬁrms mitochondrial isolation. Blots
were stripped with buffer (62.5 mmol/L Tris-Cl, 2% SDS, and
100 mmol/L β-mercaptoethanol at pH 6.8), and then probed with spe-
ciﬁc antibodies against VDAC or ANT.
2.7. In-gel tryptic digestion of protein bands
Protein bands from silver-stained gels were excised and cut into
small pieces and then subjected to in-gel digestion by trypsin as
described by Newman et al. [32]. In brief, after destaining silver
ions with a 1:1 solution of 100 mmol/L Na2S2O3 and 30mmol/L
K3Fe9(CN)6, the gel pieces were dehydrated with 50% acetonitrile and
then 25 mmol/L (NH4)HCO3/50% acetonitrile (pH 8.0). The dehydrated
gel pieces were dried and then digested with 40 ng trypsin in 100 μl of
25 mmol/L (NH4)HCO3 (pH 8.0) overnight at 37 °C. Tryptic fragments
were extracted from gel slices with acetonitrile/triﬂuoroacetic acid
(TFA)/water (70:0.1:29.9 v/v/v). Extracted samples were dried and
prepared either for LC–MS/MS or MALDI-TOF MS analysis.
2.8. Protein identiﬁcation by LC–MS/MS mass spectrometry
Extracted tryptic fragments were subjected to LC–MS/MS analysis
using a LTQ (Thermo-Fisher) MS coupled to a Surveyor HPLC system
equipped with a Micro AS auto sampler. Separation of tryptic peptideswas achieved online before MS/MS analysis on an Aquasil, C18 PicoFrit
capillary column (75 mm×100 mm; New Objective) with the following
conditions: mobile phase A, 0.1% formic acid containing 5% acetonitrile;
and mobile phase B, 0.1% formic acid in 95% acetonitrile, respectively. A
180 min linear gradient was applied. The ions eluted from the column
were electro-sprayed at a voltage of 1.75 kV. MS/MS spectra data were
analyzed using the SEQUEST search engine and analysis carried out via
the Visualize software program [33]. The SEQUEST search parameters
were set with no ﬁxed modiﬁcation, one missed trypsin cleavage site, a
peptide tolerance of 1.2 Da, and a MS/MS tolerance of 0.8 Da, and then
searched against the rodent subset of the Uniprot database. All proteins
identiﬁed had to meet a False Discovery Rate (FDR) of 1.5% or less.
2.9. Protein identiﬁcation by MALDI-TOF mass spectrometry
MALDI-TOF MS was also performed as described by Newman et al.
[32]. Brieﬂy, the dried extracted samples were resuspended in 20 μl
0.1% TFA and subjected to puriﬁcation using Micro-C18 Zip-Tips
(Millipore). The puriﬁed samples were eluted in 1–2 μl volume of α-
cyano-4-hydroxycinnamic acid in 60% acetonitrile/0.1% TFA and then
directly loaded on the sample plate for analysis using a Voyager DE
PRO MALDI-TOF mass spectrometer in positive ion, reﬂector, delayed-
extraction mode (Applied Biosystems). Peptide masses were analyzed
using the Protein Prospector software (http://prospector.ucsf.edu/
prospector/mshome.html).
2.10. Nitration of recombinant VDAC induced by exogenous ONOO− in
vitro
Because VDAC was identiﬁed as a key tyr-N protein after cardiac
IR injury, we further explored for speciﬁc VDAC tyr-N residues and
determined if tyr-N of VDAC affects its structure and function. To do
so we exposed recombinant VDAC (rVDAC) to different concentra-
tions of exogenous ONOO− to induce concentration-dependent nitra-
tion of rVDAC in vitro. Rat VDAC-1 full-length cDNA (GenBank:
BC072484, purchased from Open Biosystems) was cloned into pET-
21a vector (Novagen) and expressed in BL21 cells. rVDAC proteins
were extracted with BugBuster Master Mix (Novagen) and puriﬁed
with Ni-NTA His·Bind Resins (Novagen). Puriﬁed rVDACwas refolded
at 4 °C by dropwise dilution of one volume protein with 10 volumes
refolding buffer containing 20 mmol/L Tris-Cl, 100 mmol/L NaCl, 1%
lauryldimethylamineoxide (LDAO), and 1 mmol/L DTT at pH 7.4
[34,35]. It has been reported that using the detergent LDAO resulted
in a 90% refolding of rVDAC compared to 75% and 30% for the deter-
gents DDM or C8E4, respectively [35]. After refolding, the refolded
rVDAC protein was dialyzed against refolding buffer, without DTT, at
4 °C to remove the DTT. The reconstituted rVDAC was used for in vitro
nitration by ONOO−. ONOO− (Calbiochem) concentration was deter-
mined by absorbance at 302 nm with an extinction coefﬁcient of
1670 M−1 cm−1 in 100 mmol/L of NaOHprior to use [36]. For exposure
of rVDAC to ONOO−, 500 μg of rVDAC at 3 mg/ml was incubated with
0–400 μmol/L ONOO− at 23 °C for 30 min. The ONOO−-treated rVDAC
was subjected to SDS-PAGE or 2-DE, followed by Western blot with
antibodies against 3-NT and VDAC, or gels were stained with silver
staining and VDAC bands were cut for MALDI-TOF MS.
2.11. Reconstitution of rVDAC into planar lipid bilayers for channel
activity
Channel activity of rVDAC was monitored by incorporating rVDAC
into planar lipid bilayers (PLB), as previously described [37]. Brieﬂy,
phospholipids were prepared by mixing phosphatidylethanolamine,
phosphatidylserine and phosphatidylcholine (Avanti Polar Lipids,
Alabaster, AL) in a ratio of 5:4:1 (v/v); the phospholipids were dried
under N2 and re-suspended in n-decane to a ﬁnal concentration of
25 mg/ml. The cis/trans chambers contained identical solutions of
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The cis chamber was held at virtual ground and the trans chamber
was held at the command voltages. rVDAC protein was added into the
cis chamber. After channel incorporation into the bilayer, ONOO− was
added to the cis chamber and diluted proportionally to achieve the
desired concentration of 50 μmol/L. Currents were sampled at 5 kHz
and low pass ﬁltered at 1 kHz using a voltage clamp ampliﬁer
(Axopatch 200B, Molecular Devices) connected to a digitizer (DigiData
1440,Molecular Devices), and recorded in 1 min segments. The pClamp
software (version 10, Molecular Devices) was used for data acquisition
and analysis. Additional analyses were conducted using Origin 7.5
(OriginLab).
2.12. Statistical analysis
All results are expressed asmeans±SEMandwere analyzed by one-
way ANOVA followed by a post-hoc analysis (Student–Newman–Keuls'
test) to determined statistically signiﬁcant differences of means among
groups. A value of pb0.05 was considered signiﬁcant (two-tailed).
3. Results
3.1. O2
•− and ONOO− production increase in isolated hearts during IR injury
DHE ﬂuorescence (O2•− emission) increased during ischemia; on
reperfusion, it declined abruptly, but remained higher than baselineD
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Fig. 1. Time course of changes in superoxide (O2•−) and peroxynitrite (ONOO−) levels
during IR. A: The ﬂuorescence probe DHE, via its stable (ethidium) or unstable and
labile 2-hydoxyethidium (2-OH-E+) product was used to assess intracellular O2•− emis-
sion online in isolated hearts at the LV free wall. B: Dityrosine (DiTyr) ﬂuorescence
formed from L-tyrosine in the presence of ONOO−was used to monitor ONOO− online
similar to that described for the DHE ﬂuorescence probe. TC: Time control; IR10:
30 min ischemia and 10 min reperfusion; N=4–5 hearts/group/probe; Values are
mean±SEM. *: pb0.05 vs. TC. See Table 1 for functional data.values (Fig. 1A, IR10), consistent with our previous ﬁndings [7,23,26].
Similarly, DiTyr ﬂuorescence (ONOO−) increased and remained elevat-
ed during ischemia; on reperfusion it decreased to baseline levels
(Fig. 1B, IR10). Time control (TC) groups showed no signiﬁcant changes
in DHE (O2•−) and DiTry (ONOO−) ﬂuorescence during the duration of
the perfusion protocol (Fig. 1A and B, TC).
These changes in O2•− and ONOO− generation also correlated with
the changes of function in isolated hearts. Systolic–diastolic left ven-
tricular pressure (dLVP), indices of contractility and relaxation
(dLVP/dtmax and dLVP/dtmin) respectively decreased, while diastolic
LVP increased during ischemia (Table 1, IR10, IR60); during reperfusion,
dLVP/dtmax, dLVP/dtmin and dLVP recovered to almost half the pre-
ischemia values while diastolic LVP remained signiﬁcantly higher
than the pre-ischemia level (Table 1, IR10, IR60). Cardiac function
was unchanged over time in the TC groups (see Online Supplement
Table S3). Heart rate was unchanged on reperfusion compared to pre-
ischemia in all groups (Table 1).
3.2. Mitochondrial protein tyr-N increases after cardiac IR injury
The isolated heart experiments strongly implicated the potential for
cardiac protein tyr-N, as a marker of ONOO−-induced dPTMs. Because
mitochondrial dysfunction plays a key role in IR injury, we assessed
concurrently the extent of mitochondrial protein tyr-N. Mitochondria
isolated from TC, I30, IR10, IR30 and IR60 groups were subjected to
Western blotting with anti-3-NT antibody. Several immunoreactive
bands were detected in all groups (Fig. 2A). Compared to TC, IR caused
an increase in anti-3-NT band signal intensity at 35 kDa and 15 kDa. To
exclude the possibility that stronger anti-3-NT signals were derived
from large amounts of protein loaded, we chose ANT (~35 kDa) protein
as the loading control, which was similar in all groups (Fig. 2A). Com-
parison of the ratio of densities of anti-3-NT bands to anti-ANT bandsTable 1
Cardiac function in IR10, 60, resveratrol and L-NAME treated IR10 groups during baseline,
ischemia 30 min and reperfusion 10 and 60 min.
Variable Pre-ischemia Ischemia
30 min
Reperfusion
10 min
Reperfusion
60 min
dLVP/dtmax (mm Hg/s)
IR10, 60 2440±119 23±1 1450±172 1550±151
IR10+RES 2429±104 25±1 1913±119⁎
IR10+L-NAME 2778±191 23±1 1799±119⁎
dLVP/dtmin (mm Hg/s)
IR10, 60 −2178±128 −32±2 −1151±162 −1255±140
IR10+RES −2140±83 −29±1 −1944±190⁎
IR10+L-NAME −2290±134 −29±1 −1722±83⁎
Sys-dia LVP (mm Hg)
IR10, 60 88±4 0.1±0 38±5 39±4
IR10+RES 90±4 0.1±0 57±7⁎
IR10+L-NAME 95±5 0.1±0 64±4⁎
Diastolic LVP (mm Hg)
IR10, 60 0±0 10±3 17±3 16±3
IR10+RES 0±0 1±1⁎ 3±2⁎
IR10+L-NAME 0±0 3±2⁎ 4±2⁎
Coronary ﬂow (ml/min)
IR10, 60 21.2±2.2 0±0 18.6±2.4 19.3±2.2
IR10+RES 21.6±1.8 0±0 19.4±1.4
IR10+L-NAME 16.3±2.2⁎ 0±0 15.4±1.6⁎
Heart rate (beats/min)
IR 10,60 215±5 0±0 212±6 213±4
IR10+RES 210±3 0±0 214±7
IR10+L-NAME 215±4 0±0 220±4
IR10: 30 min of ischemia and 10 min of reperfusion; IR60 only in non-treated group;
sys–dia LVP, systolic–diastolic left ventricular pressure; dLVP/dtmax, index of contractility;
dLVP/dtmin: index of relaxation; N=8–10 hearts/group. Values aremean±SEM. *pb0.05:
IR10+RES, IR10+L-NAME vs. IR10, 60.
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mitochondrial proteins were monitored with anti-ANT antibody. B: Densitometric analysis
of Western blot of tyr-N of mitochondrial proteins. The densities of anti-3-NT bands at
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after which % density of each anti-3-NT bands was normalized to % density of their
correspondingANT bands. A is a representative blot andB is themean±SEMof four exper-
iments. *: pb0.05 vs. TC group. TC: time control; I: Ischemia; R: Reperfusion. MW:molecu-
larweight. C:Mitochondrial proteins isolated from IR groupswere subjected to IPwith anti-
3-NT antibody followed by Western blots with indicated antibodies. Lanes 1 and 3: total
mitochondrial protein lysates (input); lanes 2 and 4: IP with anti-3-NT antibody. MW:
molecular weight; WB: Western blot. D: VDAC from mitochondrial protein of TC and IR10
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immunoreaction occurred in the IR groups.
3.3. Identity of tyr-N mitochondrial proteins with speciﬁc antibodies and
mass spectrometry
To identify the enhanced tyr-N proteins implicated by the Western
blot above (Fig. 2A), we subjected the total mitochondrial protein
extracts from IR groups to IP with an anti-3-NT antibody. After IP, theimmunoprecipitates were subjected to SDS-PAGE to remove the deter-
gent and collect sample for LC–MS/MS assay. After the immunoprecip-
itates entered the separating gel part of the SDS-PAGE gel from
loading wells, the gel was run for 5 min and then silver stained. The
silver stained protein areas on the gel that include all sizes of proteins
were collected and cut into two parts for LC–MS/MS (Fig. S1 lane 1,
Online Supplement). Initially, 13 mitochondrial proteins were obtained
from immunoprecipitates of the anti-3-NT (Table S1, Online Supple-
ment). Four of these were polypeptides from the ETC and ﬁve were
components of the TCA cycle. Notably, two proteins, VDAC and ANT,
with molecular weights of about 35 kDa, which are similar to the
above Western blot 35 kDa tyr-N protein band size (Fig. 2A), were
also obtained. This indicated that these two proteins might be candi-
dates of tyr-N mitochondrial proteins.
We used protein speciﬁc antibodies to further identity tyr-N pro-
teins displayed on the Western blots. Based on molecular weights of
the candidate proteins listed in Online Supplement Table S1 and on
Western blot analyses (Fig. 2A), we focused on identifying whether
ANT and/or VDAC was the 35 kDa tyr-N protein. IP assays of mitochon-
drial protein extracts of IR groups were carried out with anti-3-NT anti-
body followed by Western blotting with antibodies against VDAC and
ANT. Immunoreactive signals were detected when the VDAC antibody
was used to probe anti-3-NT immunoprecipitates (Fig. 2C, Lane 4).
This corresponded to a similar size 35 kDa band in the total mitochon-
drial protein lysate probed with anti-VDAC antibody (Fig. 2C, Lane 3,
input) or probed with anti-3-NT antibody (Fig. 2A). In contrast, when
ANT antibody (Fig. 2C, Lane 2) was used no immunoreactive signal
was detected from the anti-3-NT immunoprecipitates. These data
strongly implicated VDAC as the 35 kDa protein exhibiting enhanced
tyr-N after IR injury. A 15 kDa mitochondrial protein also displayed
enhanced tyr-N in IR groups on Western blot and we also found 3 pro-
teins with molecular weights about 15 kDa (see Online Supplement
Table S1); identity of these tyr-N proteins is as yet incomplete; our
intent here was to focus only on VDAC.
Next we utilized an approach reported by Tran et al. [38] to compare
the relative ratio of nitrated VDAC to total VDAC between the TC and IR
groups. Based on Fig. 2A results, at the 35 kDa protein, the IR10 group
displayed a similar tyr-N level as the IR60 group, but higher than the
IR30 group. Therefore, we chose the IR10 group to compare with the
TC in this and all other experiments. Mitochondria were isolated as de-
scribed in Method (see Method 2.3) from TC and IR10 hearts. VDAC
was ﬁrst immunoprecipitated with anti-VDAC antibody (Sigma) from
mitochondrial protein lysate of TC and IR10 groups individually. The im-
munoprecipitates were subjected to Western blotting with anti-3-NT
antibody, and then the membranes were stripped and reblotted with
anti-VDAC antibody (Cell Signaling). The resulting Western blots
showed that similar amounts of VDAC protein were immuno-
precipitated from the TC and IR10 groups (Fig. 2D, bottom panel),
whereas immunoprecipitated tyr-N VDAC increased in the IR10 group
compared to the TC group (Fig. 2D, upper panel). Comparison of the rel-
ative ratio of the tyr-N VDAC bands to the total VDAC bands clearly con-
ﬁrmed that IR increased VDAC nitration signiﬁcantly by approximately
4 fold (Fig. 2E). This result (Fig. 2D, E) was similar to the result of West-
ern blotting with anti-3-NT shown in Fig. 2A and B, which displayed a
35 kDa protein (identiﬁed as VDAC) with a higher tyr-N level in the IR
than in the TC group.
To further conﬁrm tyr-N of VADC, mitochondrial proteins from TC
and IR10 groups were subjected to 2-DE individually, followed by
Western blots with anti-3-NT antibody. After blotting with anti-3-
NT antibody, the membranes were stripped and then reblotted with
anti-VDAC antibody. The results showed that VDAC spots (solid tilted
arrows) displayed strong immunoreactivity to anti-3-NT antibody in
the IR10 group (Fig. S2B, D, Online Supplement), whereas in the TC
group, the VDAC spot (dotted tilted arrows) showed only a slight
immunoreactive signal with anti-3-NT antibody (Fig. S2A, C, Online
Supplement). Why two VDAC spots showed immunoreactivity to
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in the IR10 group is unclear at this time.3.4. ONOO− induces tyr-N of rVDAC in vitro
The aim of these experiments was to identify speciﬁc tyr-N residues
and further conﬁrm tyr-N of VDAC. Puriﬁed rVDAC was exposed to
ONOO− (0–400 μmol/L) and the ONOO−-treated rVDAC protein was
subjected to Western blotting with anti-3-NT antibody. Our approach
showed that rVDAC can be nitrated by as low as 10 μmol/L of ONOO−
(Fig. 3A); moreover, signal intensity of tyr-N of rVDAC increased as
[ONOO−] increased. Some tyr-N of rVDAC protein exhibited slowmobil-
ity on the SDS-PAGE gel. In addition to the 35 kDa bands (rVDAC
monomer), additional bands with molecular weights of approximately
65 kDa, 100 kDa, and higher appeared. This indicated formation of
higher molecular mass species (Fig. 3A) and suggested that tyr-Ninduced a structural alteration of rVDAC that led to protein
oligomerization.
In addition, we examined the characteristics of rVDAC incubated
with ONOO− by 2-DE. In this experiment, we chose one concentration
of ONOO−, i.e. 200 μmol/L, to treat rVDAC. After treatment rVDAC
appeared as 4 adjacent spots (Fig. S3B and D, Online Supplement);
three of these spots revealed equal signal intensities to anti-3-NT
antibody and to anti-VDAC antibody, whereas most of the control
(non-nitrated) rVDAC were accumulated at two adjacent spots and
showed no immunoreactivity to anti-3-NT antibody (Fig. S3A and C,
Online Supplement).
To identify possible tyr-N residues in the rVDAC, we excised
ONOO−-untreated (0 μmol/L) and 100, 200, 400 μmol/L ONOO−-treated
rVDAC bands on silver stained SDS-PAGE gels, and then subjected them
to MALDI-TOF MS. The sensitivity of the MALDI-TOF MS assay is lower
than that of the Western blots, because in the MS analysis only 1–2 μl
of trypsin-digested sample was loaded on the sample plate, and the
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this experiment 100, 200, 400 μmol/L of ONOO− was used to treat
rVDAC. Nine of 11 total tyr residues (Y) of rVDAC were detected
by MALDI-TOF MS, speciﬁcally, 22Y, 62Y, 67Y, 146Y, 153Y, 173Y, 195Y,
225Y and 247Y (Online Supplement Table S2). Among the identiﬁed
Y-containing peptide fragments, one fragment, 62YRWTEYGLTFTEK74,
displayed a +45 mass units' shift from m/z 1693 to 1738 in ONOO−-
treated rVDAC (Fig. 3B), consistent with a single NO2 group added to
either 62Y or 67Y. In ONOO−-untreated (control) rVDAC, the intensity
of spectrum m/z 1693 was highest among all four groups, while the
spectrumm/z 1738was absent. In ONOO−-treated rVDAC, the intensity
of spectra m/z 1693 decreased gradually with increasing [ONOO−],
while spectra m/z 1738 appeared among the three ONOO−-treated
rVDAC groups (Fig. 3B). The site(s) identiﬁed in ONOO−-treated
rVDAC may or may not be the same as in native VDAC after IR injury.
3.5. Resveratrol or L-NAME treatments reduce mitochondrial
protein tyr-N
We next examined if the enhanced protein tyr-N during IR is attrib-
utable to the increases in ONOO− formation resulting from combined
generation of NO• andO2•−. Heartswere treatedwith L-NAMEor RES be-
fore 30 min ischemia, followed by IR, and tyr-N of mitochondrial pro-
teins was again evaluated as described above (see Results 3.2) by
Western blot with anti-3-NT antibody. Both RES and L-NAME reduced
tyr-N of 35 kDa (identiﬁed asVDAC) and 15 kDamitochondrial proteins
compared to the untreated group (Fig. 4A, B). These data indicated that
ONOO−produced during IR injury inducedmitochondrial protein nitra-
tion, in particular tyr-N of VDAC.
To correlate the preventive effects of L-NAME and RES onmitochon-
drial protein tyr-N with cardioprotection during IR injury, we moni-
tored ONOO− and O2•− production online in isolated hearts. L-NAMEA 
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resveratrol; L-NAME: NG-nitro-L-arginine methyl ester; MW: molecular weight.attenuated DiTyr ﬂuorescence (ONOO−) levels during ischemia
(Fig. 5B). We showed previously that L-NAME reduced cold-induced
ONOO− production, but that it did not alter O2•− emission [24]. Because(µmol/L)
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tor the O2•− emission with DHE ﬂuorescence. RES attenuated DHE ﬂuo-
rescence (O2•−emission) induced during ischemia and completely
blocked it during reperfusion (Fig. 5A). Reduction of DiTyr/DHE ﬂuores-
cence by L-NAME and RES was associated with a signiﬁcant improve-
ment in cardiac function during reperfusion (Table 1). Collectively,
reducing ONOO−/O2•− production during IR decreased protein tyr-N,
and at the same time improved recovery of function on reperfusion.
3.6. Resveratrol reduces rVDAC tyr-N in vitro
To verify that L-NAME and RES attenuated VDAC tyr-N during IR,
rVDAC was incubated with ONOO− (0–100 μmol/L), with or without
RES or L-NAME; rVDAC tyr-N was evaluated again by Western blot
using anti-3-NT antibody. Incubation with ONOO− resulted in tyr-N
of rVDAC (Fig. 6A). RES, 100 μmol/L, abolished tyr-N of rVDAC,
while L-NAME (100 μmol/L) had no effect. The inhibitory effect of
RES on ONOO− induced rVDAC tyr-N was concentration-dependent,
such that greater than 10 μmol/L RES inhibited rVDAC tyr-N induced-200 
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all-points amplitude histograms are also shown.by 20 μmol/L of ONOO− (Fig. 6B). This suggests that L-NAME inhibits
only generation of NO• in the presence of NOS, whereas RES scavenges
both O2•− and ONOO−.
3.7. ONOO− enhances rVDAC conductance
We next investigated if ONOO− altered rVDAC activity by recording
single channel conductance after reconstituting rVDAC into PLB.We as-
sumed that ONOO− is the major species inducing tyr-N of rVDAC.
rVDAC exhibited a characteristic voltage-dependent conductance
(Fig. 7A), which is similar to native VDAC (Fig. S4, right panel, Online
Supplement) [37]. The effect of ONOO− on rVDAC was monitored at a
membrane potential of −10 mV. Under control conditions, primary
rVDAC chord conductance was approximately 1.8 nS as depicted by
the unitary current amplitude of 18 pA (Fig. 7B). When 50 μmol/L
ONOO− was added, channel activity was enhanced with multiple
higher conductance states, as evidenced by current amplitudes of
−25 pA and −30 pA (Fig. 7B). These experiments demonstrate that
50 μmol/L ONOO− directly enhanced rVDAC conductance. 
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The functional and biological consequences of tyr-N depend on
whichproteins are nitrated aswell as on the extent and sites of nitration
in a given protein [39]. Identifying tyr-N of mitochondrial proteins
should help to deﬁne the potential pathogenic role of this dPTM in
disease states and to provide guidance on howandwhere to target ther-
apies against these dPTMs. Although there are prior reports [8,17] that
IR injury induces tyr-N of mitochondrial proteins, only a few proteins
so far have been identiﬁed, and there has been no direct evidence for
VDAC nitration or for speciﬁcally nitrated tyr residues. Here we used
proteomic analyses and IP assays to search for speciﬁc proteins that un-
dergo enhanced tyr-N during IR in isolated perfused hearts. We found
that VDAC, a key and abundant outer mitochondrial membrane
(OMM) protein was targeted for tyr-N during IR. Consistent with our
isolated heart results, the in vitro experiments conﬁrmed that rVDAC
can be nitrated by ONOO− at either the 62Y or 67Y site. In addition,
our results indicate that rVDAC tyr-N may trigger oligomerization of
rVDAC and that ONOO− enhances rVDAC channel conductance. Thus,
nitration of VDAC likely induces alterations in both its structure and
function.
To further explore mechanisms of tyr-N induction, RES or L-NAME
was perfused into isolated hearts before ischemia as well as applied to
rVDAC protein. In isolated hearts, both RES and L-NAME decreased
VDAC tyr-N, inhibited formation of ONOO−, and improved cardiac
function after IR. In vitro, RES, but not L-NAME, directly prevented
tyr-N of rVDAC induced by ONOO−. Lastly, in vitro tyr-N of rVDAC
conﬁrmed our ex vivo results that RES indeed can scavenge ONOO−
to reduce tyr-N. Overall, our study suggests that VDAC tyr-N occurs
during IR injury and that scavenging O2•−/ONOO− and attenuating
NO• generation reduces tyr-N of VDAC during IR.4.1. Sites of VDAC tyr-N and functional change
Previous studies suggested that VDAC tyr-N can occur in mouse
hearts during IR injury [17], in old-aged rat hearts [31], and in rat hippo-
campal tissue after acute smoke inhalation [40]. In those studies, VDAC
was suggested as a nitrated protein based on MS analysis for anti-3-NT
positive protein spots on 2-DE gels or anti-3-NT IP protein mixtures.
However, there was no direct evidence of VDAC tyr-N or of attenuated
VDAC tyr-N by inhibitors/scavengers of ONOO−. Moreover, the impact
of tyr-N on rVDAC channel conductance was unknown. Based on our
multifaceted approaches involvingMS analysis, IP, and electrophysiolo-
gy, we provide ﬁrm evidence that VDAC tyr-N occurs during cardiac IR
injury. Moreover, tyr-N appears to oligomerize rVDAC and ONOO−
increases the rVDAC channel conductance state. We also newly report
that partial prevention of VDAC tyr-N is associated with improved
cardiac function.
Protein tyr-N is a selective process, in so far as not all proteins can
be nitrated. The potential for a protein to become nitrated is affected
by the cellular and subcellular localization of a given protein [41].
Most nitrating agents are short-lived [42,43], so proteins to be
nitrated must lie in close proximity to the site of ONOO− formation.
Because NO• is a diffusible molecule and O2•− is diffusion limited and
generated primarily in mitochondria, ONOO− is most likely formed
in mitochondria. As the most abundant protein in the OMM, VDAC
is likely highly exposed to ONOO−. Thus it is probable that VDAC is
an easy target during IR injury for attack by ONOO− with subsequent
tyr-N.
We examined for a direct functional impact of ONOO− on VDAC by
treating rVDAC incorporated into PLB with ONOO− and found that
50 μmol/L ONOO− enhanced rVDAC channel activity, as shown as
multiple higher conductance states. This may allow increased transport
of metabolites across a “leakier” OMM. It is possible that the higher
conductance states permit release of cytochrome c across the OMMvia VDAC, independent of mitochondrial permeability transition pore
(mPTP). How ONOO− enhances VDAC channel conductance is unclear.
Despite our ﬁnding that ONOO− induced higher rVDAC channel
conductance states, it is not established if higher or lower VDAC channel
conductance states contribute to impaired mitochondrial function dur-
ing cardiac IR injury. We reported recently a concentration-dependent,
biphasic inhibitory effect of exogenous NO• on cardiac VDAC [37]. Peak
inhibition occurred at a physiologically relevant level of NO•, and this
correlated with a delay in mitochondrial permeability transition
pore (mPTP) opening. Consequently, a NO•-induced delay in mPTP
opening, in tandem with an induced low conducting state of VDAC,
could potentially contribute to myocardial protection. This would then
support our hypothesis that the ONOO−-induced high conductance
state of VDAC is detrimental to cardiac function, whereas the putatively
protective NO•-induced low conductance state is beneﬁcial.
It is likely that ONOO−-inducedVDAC tyr-N leads to structural alter-
ations because tyr-N renders the neutral tyr residue a charged residue;
this could alter the tertiary structure of VDAC. Indeed, we found that
nitration of rVDAC caused it to oligomerize into dimers or trimers
(Figs. 3, 6). Keinan [44] reported that oligomerization of VDAC1 was
associated with cytochrome c release and apoptosis induced by various
stimuli inmany cell types. Althoughwedid not showdirectly that VDAC
tyr-N is associated with cell death, our recent data indicate that IR-
induced release of cytochrome c [45] occurs at the same time as tyr-N
ofmitochondrial proteins (and in particular, VDAC based on our current
study). Thus our study suggests that VDAC tyr-Nmay be associatedwith
mitochondrial-mediated cell death.
A rVDAC residue that is a target of nitration was narrowed to either
62Y or 67Y. The speciﬁc tyr residues capable of tyr-N are determined by
both the protein's structure and the local environment around the tyr
(Y) residues [41]. Most tyr-N residues have been found in loop struc-
tures in the vicinity of turn-inducing amino acids such as proline or
glycine [41,46]. The proximity of negatively charge residues, such as
glutamic or aspartic acids, also beneﬁts nitration of tyr [41,46]. In
our tyr-N containing peptide sequence, 67Y is adjacent to the turn-
inducing residue glycine and the negatively charge residue glutamic
acid, which conforms well to common features of structural determi-
nants of protein tyr-N. In addition, based on elucidation of the three-
dimensional structure of VDAC, 67Y is located in the loop region
between the β3 and β4 strands [47]. Consequently, 67Y is likely the
nitrated residue in the rVDAC, but for now nitration of 62Y cannot be
excluded.
4.2. Reduced mitochondrial protein tyr-N occurs with improved recovery
after IR injury
There is now ample evidence that RNS/ROS-induced protein tyr-N is
a critical factor underlying cardiac IR injury [19,48]. Inhibiting NOS
activity reduced both the level of protein nitration and the extent of IR
injury [5]. Our present and prior studies, in which we measured
ONOO−, i.e. DiTyrﬂuorescence, in the left ventricle [24] and in coronary
efﬂuent [4], demonstrate that inhibiting NOS with L-NAME can attenu-
ate the increase in ONOO− induced during IR injury (Fig. 5B). To sup-
port these prior heart studies, we report here that L-NAME also
decreased IR-induced mitochondrial proteins tyr-N (Fig. 4A), while
improving functional recovery during reperfusion (Table 1). The rapid
fall in DiTyr ﬂuorescence signal for ONOO− on reperfusion in isolated
hearts is due to washout of free DiTyr in the efﬂuent. Overall, reducing
VDAC tyr-N by attenuating NO• generation, and thus ONOO−, by
L-NAME may play a supportive role in ameliorating IR injury.
To further evaluate the effects of mitochondrial protein tyr-N in IR
injury, we tested effects of an inhibitor/scavenger of RNS/ROS, i.e. RES,
on reducing protein tyr-N and improving functional recovery. RES is
purported to have anti-inﬂammatory, anti-aging, anti-neoplastic, and
cardioprotective properties [49]. RES may react directly with ONOO−
to act as a functional ONOO− scavenger in vitro and thereby to prevent
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induced O2•− emission in cardiomyocytes has been reported [51], RES
treatment during ischemia in intact hearts involved scavenging or
inhibiting O2•−/ONOO−, with a subsequently decreased mitochondrial
protein tyr-N, has not been reported.
We report here for the ﬁrst time that RES treatment partially
inhibited DHE ﬂuorescence (emission of O2•−) induced during ischemia,
and abolished it during reperfusion in intact perfused hearts, as well as
reducedmitochondrial protein tyr-N. Goh et al. [51] reported in isolated
perfused rat hearts that RES treatment during IR reduced LDH release,
improved post-ischemic recovery of LV function, and increased Akt
and p38MAPK activity. In our study, we also found that RES, given just
before ischemia and present in hearts during ischemia, improved cardi-
ac function after IR, which is consistentwith the report of Goh et al. [51].
In addition, our in vitro experiments with rVDAC showed that RES di-
rectly, and completely, inhibited tyr-N of rVDAC induced by ONOO−
while L-NAME did not. Thus, RES is likely an inhibitor of O2•− emission,
and/or a scavenger of ONOO−; it not only reduced tyr-N of mitochon-
drial proteins, speciﬁcally VDAC after IR injury, but also improved cardi-
ac contractility and relaxation. Although RES has been shown to
stimulate NOS to generate NO• when given to precondition hearts
against IR injury [43], it is likely in our experiments that much of NO•
produced was converted to ONOO− because of abundant O2•−, which
then leads to nitration of VDAC.
We have implied that ONOO− is in large part responsible for the
observed tyr-N and that the major effect of ONOO− is to induce tyr-N.
Thus, limitations of our study are that ONOO− may induce PTMs of
not only tyr, but also of other aromatic residues and that tyr may be
additionally nitrated by non-ONOO− oxidants, such as other nitrites
and peroxidases.
In summary, we have identiﬁed VDAC as one of the mitochondrial
proteins that undergoes enhanced tyr-N during IR injury. L-NAME and
RES likely attenuate VDAC tyr-N in the ex vivo model, but only RES
abolished ONOO−-induced VDAC nitration in vitro, because there was
likely no NO• present. Moreover, inhibition of tyr-N of VDAC by L-
NAME, and especially by RES, not only demonstrates that VDAC tyr-N
occurs, but also that attenuating ONOO− production reduces tyr-N of
VDAC and concomitantly improves cardiac function after IR. Tyr-N in
ONOO−-treated rVDAC is selective and site-speciﬁc, and was accompa-
nied by rVDAC protein oligomerization. ONOO−-treated rVDAC also
leads to an enhanced channel conductance state. The results obtained
in this study indicate that VDAC, possibly with other unidentiﬁed mito-
chondrial tyr-N proteins, plays a critical role in mediating cardiac dys-
function during IR injury. Targeting against speciﬁc protein tyr-N sites
may represent a unique way to protect mitochondrial proteins and or-
gans against oxidative damage.Sources of funding
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